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Abstract Fibrates activate peroxisome proliferator activat-
ed receptor α and exert beneficial effects on triglycerides,
high-density lipoprotein cholesterol, and low density lipo-
protein subspecies. Fenofibric acid (FA) has been studied in
a large number of patients with mixed dyslipidemia, com-
bined with a low- or moderate-dose statin. The combination
of FA with simvastatin, atorvastatin and rosuvastatin
resulted in greater improvement of the overall lipid profile
compared with the corresponding statin dose. The long-term
efficacy of FA combined with low- or moderate- dose statin
has been demonstrated in a wide range of patients, including
patients with type 2 diabetes mellitus, metabolic syndrome,
or elderly subjects. The FA and statin combination seems to
be a reasonable option to further reduce cardiovascular risk
in high-risk populations, although trials examining cardio-
vascular disease events are missing.
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Introduction
Fibrates have been used in the treatment of dyslipidemia
for many years. Fibrates exert their effects by activating
peroxisome proliferator activated receptor α (PPAR-α)
[1]. Fibrates are well known for their beneficial effects
on triglycerides (TG), high-density lipoprotein cholesterol
(HDL-C), and low-density lipoprotein (LDL) subclass distri-
bution [2, 3]. One of the most used fibrates, fenofibrate, has
also shown to improve many other atherosclerosis-related
variables, such as high sensitivity C-reactive protein (hsCRP),
lipoprotein-associated phospholipase A2 (LpPLA2), apolipo-
protein C-III (apoC-III), and reverse HDL cholesterol trans-
port [1, 4–10].
Fenofibrate is a pro-drug, which requires de-esterification
in the liver to fenofibric acid, the active drug, which is then
released into the plasma to activate PPAR-α in liver, vascu-
lar endothelium, adipocytes, and muscle cells [11, 12]. The
newer fibrate formulation, fenofibric acid (FA, Trilipix®,
Abbott), that was recently approved by the Food and Drug
Administration (FDA), is the choline salt of fenofibric acid.
FA is not a pro-drug and does not undergo first-pass hepatic
metabolism [13]. FA is manufactured as delayed-release
45 mg and 135 mg capsules and can be taken without regard
to meals. Upon multiple dosing, FA plasma levels reach
steady state within 8 days [14]. FA is administered once
daily [14].
In vitro studies using human liver microsomes indicate
that FA is a weak inhibitor of CYP2C8, CYP2C19, and
CYP2A6, and a mild to moderate inhibitor of CYP2C9 at
therapeutic concentrations [14, 15]. Since they are highly
protein-bound, all fibric acid derivatives may increase the
anticoagulant effect of coumarin derivatives [16, 17], thus
the International Normalized Ratio should be carefully mon-
itored. No clinically significant pharmacokinetic interaction
has been observed between FA/fenofibrate and statin admin-
istration in humans [18–20]. FA administration should be
avoided in patients who have severe renal impairment, and
dose reduction is required in patients having mild to mod-
erate renal impairment. No pharmacokinetic studies have
been conducted in patients with hepatic impairment. FA
has not been investigated in trials in pediatric patients.
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Methods
A PubMed/Scopus search was performed up to Septem-
ber 2011 using combinations of “fenofibric acid” with
the following keywords: fibrate, fenofibrate, statin, sim-
vastatin, atorvastatin, rosuvastatin, lipid-lowering medi-
cations, adverse effects, side effects, gastrointestinal,
transaminases, creatine kinase, myopathy, safety. Rand-
omised controlled trials, original papers, review articles
and case reports that provide information regarding the
pharmacology, lipid and non-lipid effects, duration of
biochemical alterations, and adverse events of FA +
statin combination are included in the present review.
References of these articles were scrutinised for relevant
articles.
Designs of major fenofibric acid trials
The efficacy and safety of FA has been evaluated in a large
well-designed phase III clinical program consisting of three
separate double-blind, randomized, active control trials
(Fig. 1)[ 21]. In each trial patients were randomized in a
ratio of 2:2:2:2:2:1 to one of six arms:
& Fenofibric acid 135 mg/day
& Low-dose statin
& Medium-dose statin
& Fenofibric acid 135 mg/day + low-dose statin
& Fenofibric acid 135 mg/day + medium-dose statin
& High-dose statin
A single statin was given in each trial:
& Simvastatin 20, 40 or 80 mg/day [22]
& Atorvastatin 20, 40 or 80 mg/day [23]
& Rosuvastatin 10, 20 or 40 mg/day [24]
Together, these studies investigated the safety and effica-
cy of FA 135 mg/day as monotherapy and combined with
three different statins [21]. The high-dose statin arms were
not used for formal statistical comparisons, but served as a
clinically relevant reference for assessment of efficacy and
safety. They are not described in detail in this review.
Primary efficacy endpoints were fasting mean/median per-
centage changes in HDL-C and TG (comparing each com-
bination with corresponding statin-dose monotherapy) and
LDL cholesterol (LDL-C) levels (comparing each combina-
tion with FA monotherapy). Inclusion criteria were elevated
TG (≥150 mg/dl or 1.69 mmol/L), decreased HDL-C levels
(<40 mg/dl or 1.03 mmol/L for men and <50 mg/dl or
1.29 mmol/L for women), and elevated LDL-C levels
(≥130 mg/dl or 3.36 mmol/L). All trials had a 6-week
dietary run-in/lipid therapy washout, a 12-week treatment
period, and a 30-day follow-up period.
Patients who completed these trials were eligible to enter
a phase III open-label 1-year extension study [25]. A subset
of these patients was in turn examined in a phase III, open-
label, 2-year extension study [26]. In the extension studies
all patients received FA 135 mg/day combined with the
moderate dose of the statin to which they had originally
been randomized (rosuvastatin 20 mg/day, simvastatin
40 mg/day or atorvastatin 20 mg/day). Their primary pur-
pose was the evaluation of the long-term safety of FA
Fig. 1 Design of the pivotal
trials evaluating the efficacy
and safety of the combined use
of fenofibric acid (FA) with
different statins in patients with
mixed dyslipidemia
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group analysis of the randomized, double-blind trials was
performed in 586 patients with mixed dyslipidemia and type
2 diabetes mellitus (T2DM) [27].
In another 8-week, randomized, double-blind study, the
effect on LDL-C levels of the administration of simvastatin
40 mg/day was compared with the fixed combination dos-
age of FA with rosuvastatin 5, 10 or 20 mg/day, in patients
(n0474) with LDL-C ≥160 mg/dl and ≤240 mg/dl and
TG ≥150 mg/dl and <400 mg/dl [28].
Alterations in lipid profiles with FA, statins
and FA + statin combinations
The three Phase III trials together enrolled approximately
2,700 patients, of whom 2,575 were available for analysis.
The FA/simvastatin study randomized 657 patients of
whom 621 were available for analysis [22]. FA + simvasta-
tin 20 mg/day produced a greater increase in HDL-C
(17.8 % vs. 7.2 %, p<0.001) and a greater decrease in TG
levels (−37.4 % vs. −14.2 %, p<0.001) and very low-
density lipoprotein cholesterol (VLDL-C) levels (−38.9 %
vs. −19.2 %, p<0.01) compared with simvastatin 20 mg/day
(Fig. 2). In addition, FA + simvastatin 20 mg/day resulted in
a greater LDL-C decrease compared with FA monotherapy
(−24.0 % vs. −4.0 %, p<0.001). Similarly, FA + simvastatin
40 mg/day produced a greater increase in HDL-C (18.9 %
vs. 8.5 %, p<0.001) and a greater decrease in TG levels
(−42.7 % vs. −22.4 %, p<0.001) and VLDL-C (−51.1 %
vs. −35.7 %, p<0.01) compared with simvastatin 40 mg/
day, as well as a greater LDL-C decrease compared with FA
monotherapy (−25.3 % vs. −4.0 %, p<0.001) (Fig. 2). FA +
s i m v a s t a t i n2 0m g / d a yr e s u lted in significantly greater
reductions in non-HDL-C, VLDL-C, total cholesterol (TC)
and apoB compared with simvastatin 20 mg/day monother-
apy (p≤0.012). FA + simvastatin 40 mg/day resulted in
similar reductions in non-HDL-C, apoB, TC, and hsCRP
compared with simvastatin 40 mg/day [22].
The FA/atorvastatin study randomized 613 patients of
whom 577 were available for analysis [23]. FA + ator-
vastatin 40 mg/day combination resulted in significantly
greaterimprovementsinTG(−42.1%vs.−23.2%,p<0.001),
VLDL-C (−53.5 % vs. −35.6 %, p<0.001) and HDL-C levels
(12.6%vs.5.3%,p00.01)comparedwithatorvastatin40mg/
day monotherapy, as well as a greater decrease in LDL-C
concentration compared with FA monotherapy (−35.4 %
vs.−3.4 %,p<0.001,Fig.3). Similar results were shown when
FA + atorvastatin 20 mg/day was compared with FA or ator-
vastatin 20 mg/day monotherapy. Treatment with FA + atorvas-
tatin 20 mg/day resulted in significantly greater improvements
in non-HDL-C compared with FA (p<0.001) and atorvastatin
20 mg/day monotherapies (p<0.05,Fig.3)[ 23].
The FA/rosuvastatin study randomized 1,455 patients of
whom 1,377 were available for analysis [24]. FA + rosuvas-
tatin 20 mg/day resulted in a significantly greater increase in
HDL-C (19.0 % vs. 10.3 %, p<0.001) and a significantly
greater decrease in TG (−42.9 % vs. −25.6 %, p<0.001) and
VLDL-C (−50.6 % vs. −42.1 %, p00.038) levels compared
with rosuvastatin 20 mg/day monotherapy (Fig. 4). Further-
more, FA + rosuvastatin 20 mg/day produced a significantly
greater LDL-C reduction (−38.8 % vs. −6.5 %, p<0.001)
compared with FA monotherapy. Similar results were ob-
served when FA + rosuvastatin 10 mg/day was compared
with rosuvastatin 10 mg/day or with FA monotherapy
(Fig. 4). FA + rosuvastatin 10 mg/day resulted in signifi-
cantly greater improvements in non-HDL-C compared with
FA (p<0.001) and rosuvastatin 10 mg/day monotherapy (p<
0.001), as well as in hsCRP (p00.013) and VLDL-C (p<
0.001) compared with rosuvastatin 10 mg/day monotherapy.
FA + rosuvastatin 20 mg/day resulted in a greater improve-
ment in hsCRP levels compared with rosuvastatin 20 mg/day
monotherapy (p00.01) [24].
In another Phase III, multicenter, randomized, double-
blind study, rosuvastatin 5 mg/day was administered with
Fig. 2 Lipid alterations (%)
with the combination of
fenofibric acid (FA) 135 mg/day
with simvastatin compared with
simvastatin alone [22]. * p<0.05
vs. corresponding statin dose.
& p<0.05 vs. FA monotherapy.
Barsrepresentmean±SEM.The
numbers with white color
represent the baseline values,
whereas the numbers with black
color represent the percent
changes. HDL-C 0 high-density
lipoprotein cholesterol, TG 0 tri-
glycerides, LDL-C 0 low-
density lipoprotein cholesterol
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758) for 12 weeks [29]. Combination treatment resulted in
significantly greater improvements in plasma concentration
of HDL-C (23.0 % vs. 12.4 %, p<0.001) and TG (−40.3 %
vs. −17.5%,p<0.001) compared with rosuvastatin monother-
apy, as well as of LDL-C (−28.7 % vs. −4.1 %, p<0.001)
compared with FA monotherapy [29].
A recent trial randomized patients to receive fixed-dose
combinations of FA 135 mg/day with rosuvastatin 5, 10 or
20 mg/day or to monotherapy with simvastatin 40 mg/day
[28]. The combinations resulted in significantly greater
decreases in plasma levels of LDL-C, non-HDL-C, apoB,
TG, hsCRP, VLDL-C, TC, and apoC-III, and a significantly
greater increase in HDL-C concentration, compared with
simvastatin 40 mg/day. For example the reductions in
LDL-C levels with FA + rosuvastatin 5, 10 and 20 mg/day
were 38.9 %, 46.0 % and 47.2 % respectively compared
with 32.8 % for simvastatin 40 mg/day (p<0.01). Signifi-
cantly higher proportions of patients in each FA/rosuvastatin
group achieved optimal levels for LDL-C (<100 mg/dl,
p<0.001), non-HDL-C (<130 mg/dl, p<0.001), apoB
(<90 mg/dl, p≤0.02), and TG (<150 mg/dl, p<0.001)
compared with simvastatin 40 mg/day monotherapy. Fur-
thermore, significantly higher proportions of patients treated
with each of the FA/rosuvastatin doses simultaneously
achieved optimal LDL-C and non-HDL-C levels, as well
as optimal levels for all five parameters (LDL-C, non-HDL-
C, apoB, HDL-C, and TG), compared with simvastatin
40 mg/day [28].
In a recent 12-week double-blind study, a total of 543
patients with TG ≥150 mg/dl and <400 mg/dl, HDL-
C <40 mg/dl (<50 mg/dl for women), and LDL-
C≥130 mg/dl wererandomizedtoFA 135 mg/day orplacebo,
eachco-administered with atorvastatin40mg/day+ ezetimibe
10 mg/day (Atorva/Eze) [30] .T r e a t m e n tw i t hF A+A t o r v a /
Eze resulted in a significantly greater improvement in HDL-C
(13.0 % vs. 4.2 %, p<0.001) and TG levels (−57.3 %
vs. −39.7 %, p<0.001) compared with Atorva/Eze. Both
groups experienced a >50 % reduction in LDL-C concentra-
tion (−52.9 % with FA + Atorva/Eze, −52.0 % with Atorva/
Eze).Furthermore,FA+Atorva/Ezeresultedinasignificantly
greater effect on non-HDL-C, apoB, apoA-I, apoC-III,
VLDL-C, and hsCRP compared with Atorva/Eze. More
patients in the triple combination achieved the combined
Fig. 3 Lipid alterations (%)
with the combination of
fenofibric acid (FA) 135 mg/day
with atorvastatin compared with
atorvastatin alone [23].
*p<0.05vs.correspondingstatin
dose.
& p<0.05vs.FA
monotherapy. Bars represent
mean ± SEM. The numbers with
white color represent the
baseline values, whereas the
numbers with black color
represent the percent changes.
HDL-C 0 high-density lipopro-
tein cholesterol, TG 0 triglycer-
ides, LDL-C 0 low-density
lipoprotein cholesterol
Fig. 4 Lipid alterations (%)
with the combination of
fenofibric acid (FA) 135 mg/day
with rosuvastatin compared with
rosuvastatin alone [24]. *p<0.05
vs. corresponding statin dose.
&
p<0.05 vs. FA monotherapy.
Barsrepresentmean±SEM.The
numbers with white color
represent the baseline values,
whereas the numbers with black
color represent the percent
changes. HDL-C 0 high-density
lipoprotein cholesterol, TG 0 tri-
glycerides, LDL-C 0 low-
density lipoprotein cholesterol
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and apoB <90 mg/dl (88.4 % vs 80.8 % in Atorva/Eze)
[30].
Long-term maintenance of FA-induced metabolic effects
The year 1 extension study reported sustained improvements
versus baseline in numerous lipid parameters including TG,
HDL-C, LDL-C, apoB, and hsCRP [25]. A total of 310
patients was enrolledand treated in theyear2 extension study,
of whom 287 (92.6 %) patients completed the study [26]. The
improvements in lipid parameters seen at 1 year were sus-
tainedfor≥2years.Pooledresultsshowedsubstantialpercent-
age changes in all efficacy variables with no evidence of
attenuation of the effects over time [26]. In the pooled year 2
population, the change from baseline to week 116
was +17.4 % in HDL-C, −46.4 % in TG, −40.4 % in LDL-
C,−47.3%innon-HDL-C,−52.8%inVLDL-Cand−37.8%
in TC levels. It should be mentioned that the observed alter-
ations in non-HDL-C, TC and VLDL-C were significantly
(p<0.02) smaller in the FA + simvastatin group compared with
the FA + atorvastatin or FA + rosuvastatin groups (Fig. 5)[ 26].
It should be mentioned that the number of patients in-
cluded in the extension studies is low and it is most likely
that highly motivated, good responders were included, a fact
that could affect the observed results.
Time courses and predictors of response
In the FA + statin trials the significant differences in all
primary lipid variables between both combination therapies
and the corresponding monotherapies were generally ob-
served after 4 weeks of treatment and sustained throughout
12 weeks [22–24]. Furthermore, the effect of treatment was
different between certain subgroups of patients. For example,
in the subgroup of patients with baseline LDL-C >160 mg/dl
(n0247) the decreases in LDL-C were similar in the FA +
simvastatin 20 and 40 mg/day (−33.2 % and −34.4 %,) and in
the corresponding simvastatin 20 mg/day (−29.0 %) and
40 mg/day (−34.9 %) monotherapy groups. FA + simvastatin
(20 or 40 mg/day) had a greater treatment effect on LDL-C
levels in women (−29.7 % and −30.3 %, respectively) com-
pared with men (−19.0 % and −20.5 %, respectively) [22].
Response to FA in patient subgroups
In a recent post-hoc analysis of the three 12-week trials, the
administration of FA + low- or moderate-dose statin in
approximately 2,000 subjects with the metabolic syndrome
was examined [31]. FA + low or moderate-dose statin re-
duced the number of patients meeting the American Heart
Association/National Heart, Lung and Blood Institute
(AHA/NHLBI) diagnostic criteria for metabolic syndrome
[32]( −35.7 % and −35.9 %, respectively) compared with
low-, moderate-, or high-dose statin monotherapy
(−15.5 %, −16.6 %, and −13.8 %, respectively) or FA
monotherapy (−25.7 %). FA + low- or moderate-dose statin
significantly decreased TG (p<0.001) and increased HDL-C
(p<0.001) levels compared with the corresponding-dose sta-
tin. Interestingly, the prevalence of patients meeting the fast-
ing blood glucose criterion decreased slightly with FA + statin
or FA monotherapy but increased slightly with the adminis-
tration of statin monotherapy. Furthermore, the mean change
in fasting glucose was significantly different between FA +
low- ormoderate-dose statin and low- or moderate-dose statin
monotherapy, respectively (p≤0.002) [31]. Statins have been
associated with a slightly increased risk for T2DM develop-
ment [33]. The finding that the FA + statin combination
attenuates the effects of statin on carbohydrate metabolism
parameters needs further investigation.
Fig. 5 Two-year lipid
alterations (%) with the
combination of fenofibric acid
(FA) 135 mg/day with
moderate-dose statin [26]. Bars
represent mean ± SD. The
numbers with white color rep-
resent the baseline values,
whereas the numbers with black
color represent the percent
changes. *p<0.05 vs. FA +
simvastatin. HDL-C 0 high-
density lipoprotein cholesterol,
TG 0 triglycerides, LDL-C 0
low-density lipoprotein
cholesterol
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line (n0586) the FA + low- or moderate-dose statin combi-
nation significantly (p<0.05) reduced HDL-C, TG, and
VLDL-C compared with the corresponding dose of statin
monotherapy [27]. However, the LDL-C reduction, al-
though similar between FA + low-dose statin and low-dose
statin monotherapy, was smaller with FA + moderate-dose
statin compared with moderate-dose statin monotherapy
(−32.6 % vs. −41.5 %, p<0.01). It should be noted that in
the subgroup with baseline LDL-C >160 mg/dl, the LDL-C
reductions were similar with FA + low- or moderate dose
statin (−45.5 % and −43.5 %, respectively) compared with
those observed with low- and moderate-dose statin mono-
therapy (−38.5 % and −47.1 %, respectively). Furthermore,
the reductions in apoB and hsCRP plasma levels were
similar between FA + low- or moderate- dose statin and
the corresponding statin dose. In this population, it was also
shown that the mean changes in fasting blood glucose levels
with FA + low- or moderate-dose statin combination were
significantly smaller (p00.038 and p00.040, respectively)
compared with the corresponding dose of statin monother-
apy, with which mean fasting glucose levels increased [27].
In the 2-year extension study, the subgroup of patients
with T2DM experienced improvement (similar with overall
population) in HDL-C (+15.0 %), TG (−42.1 %), LDL-C
(−41.8 %), non-HDL-C (−48.2 %), TC (−39.4 %) and
VLDL-C (−54.6 %) levels, that was evident up to week
116 [26].
Data concerning the effect of hypolipidemic treatment in
elderly subjects is limited. A recent post-hoc analysis eval-
uated data from patients aged ≥65 years (n0401) with mixed
dyslipidemia who received either monotherapy with rosuvas-
tatin 5, 10, or 20 mg/day or FA 135 mg/day, or combination
therapy with rosuvastatin (5, 10, or 20 mg/day) + FA 135 mg/
day, for 12 weeks in two randomized controlled trials
[34]. Each dose of combination treatment decreased signifi-
cantly the LDL-C concentration compared with FA mono-
therapy, as well as increased significantly HDL-C and
decreased TG levels, compared with corresponding doses of
rosuvastatin monotherapy (p<0.001 for all compari-
sons). LDL-C levels were not significantly different
between FA + rosuvastatin and the corresponding dose of
rosuvastatin monotherapy. The changes in LDL-C, HDL-C,
and TG in the subgroup (n0135) of elderly patients with
T2DM in this study were similar to those seen in the overall
population [34].
Safety and tolerability of FA + statin combination
Fibrates are generally safe and well tolerated. The most
frequent adverse events (AEs), which are similar to those
of statins, are gastrointestinal symptoms (nausea and
diarrhea) and musculoskeletal symptoms [myalgia and mod-
erate elevation of creatinine kinase (CK)] [1, 35, 36]. Both
fibrates and statins, especially in combination, have been
reported to cause myopathy, but the most serious adverse
effect, i.e. rhabdomyolysis, is rare if certain precautions are
taken [1, 37, 38]. Risk factors for these AEs include renal or
hepatic insufficiency, increased age, and several medica-
tions [39, 40]. The fenofibrate plus statin combination has
been reported to be safer compared with gemfibrozil plus
statin combination [41]. In The Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) study, no cases of
rhabdomyolysis were described among approximately 900
patients receiving fenofibrate plus a statin [42]. Fenofibrate
may also increase creatinine and homocysteine plasma
levels [1, 43–48].
The safety of the newer formulation of FA, alone and in
combination with low- and moderate- dose statin, was eval-
uated in the phase III clinical studies (Table 1). The results
indicate a similar AE profile between the different FA +
statin combination treatments. Furthermore, when the safety
profile was examined according to the presence or not of
metabolic syndrome, or in patients with T2DM, the AEs
were similar with those observed in the overall population
[27, 31]. Additionally, the long-term safety of FA + statin
was tested for up to 2 years [25, 26]. The most common
adverse events were headache, upper respiratory tract infec-
tion, nasopharyngitis, and back pain, with the incidence of
all adverse events being similar across all combination
treatment groups [25, 26]. In these studies, no deaths
or rhabdomyolysis were reported during 1- or 2-year
follow-up [25, 26].
It should be mentioned that even with the triple combi-
nation of FA with atorvastatin/ezetimibe there was no sig-
nificant difference in the rate of serious or treatment-related
AEs and the overall incidence of such events was low [30].
Furthermore, in elderly subjects the safety profile of FA +
rosuvastatin administration was generally similar with the
individual monotherapies [34].
In conclusion, FA + statin combination treatment did not
produce a significant increased rate of serious adverse
events compared with monotherapy.
Clinical implications
Cardiovascular disease (CVD) constitutes the leading cause
of death in developed countries. Current treatment guide-
lines focus on lowering LDL-C as the primary strategy for
reducing CVD risk [49, 50]. Statins are associated with a
significant CVD risk reduction [51, 52]. However, in the
clinical setting a large number of patients treated with lipid-
lowering therapies have persistent lipid abnormalities
[53–55]. Furthermore, it is now established that patients
250 Cardiovasc Drugs Ther (2012) 26:245–255are still at risk for CVD events, i.e. they have residual CVD
risk, even if they are receiving optimal statin treatment [56].
The residual CVD risk remains even if statins are adminis-
trated in maximum doses. For example, in the Study of The
Effectiveness of Additional Reductions in Cholesterol and
Homocysteine (SEARCH), simvastatin 80 mg/day reduced
major vascular events by only 6 % compared with simvas-
tatin 20 mg/day [57]. Furthermore, the elevation of the statin
dose was associated with an increased risk of myopathy
[57]. Residual CVD risk is at least partly explained by the
increased levels of TGs and the decreased levels of HDL-C
[58, 59]. This risk is enhanced in patients with mixed
dyslipidemia, such as T2DM patients or patients with met-
abolic syndrome, who are characterized by both increased
TG levels and decreased HDL-C concentration. Factors
which are also implicated, among others, in the increased
residual CVD risk in patients with mixed dyslipidemia are
the increased levels of the atherogenic small dense LDL
particles, of apoC-III and of inflammation-related markers,
such as hsCRP and Lp-PLA2 [60–64]. A number of
Table 1 Summary of adverse events (AEs) recorded during phase III trials of FA with statins
Study Number of
patients
Treatment
related AEs
(%)
Rate of discontinuation
due to AEs (%)
% patients experiencing AE
Myalgia Abnormal liver
function tests
a
Increased
creatine
kinase
b
Rhabdo-
myolysis
FA and simvastatin [22] 591 23.9 14.6 4.1 0.8 0.5 0
FA 135 mg/day 119 32.8 NR 5.0 4.2 0 0
Simvastatin 20 mg/day 119 16.0 11.8 3.4 0 0 0
FA 135 mg/day +
simvastatin 20 mg/day
119 22.7 NR 4.2 0 0.8 0
Simvastatin 40 mg/day 116 24.1 NR 5.2 0 1.7 0
FA 135 mg/day +
simvastatin 40 mg/day
118 23.7 NR 2.5 0 0 0
FA and atorvastatin [23] 554 16.0 8.5 4.1 1.1 0.2 0
FA 135 mg/day 112 12.5 7.1 2.7 0 0 0
Atorvastatin 20 mg/day 113 6.2 2.7 4.4 0 0.9 0
FA 135 mg/day +
atorvastatin 20 mg/day
110 20.0* 10.9* 1.8 2.7 0 0
Atorvastatin 40 mg/day 109 18.3 11.0 7.3 0 0 0
FA 135 mg/day +
atorvastatin 40 mg/day
110 22.7 12.7 4.5 2.7 0 0
FA and rosuvastatin [24] 533 NR NR 2.6 0.9 0.2 0
FA 135 mg/day 105 NR NR 1.0 1.9 0 0
Rosuvastatin 10 mg/day 105 16.9 NR 5.7 0 0 0
FA 135 mg/day +
rosuvastatin 10 mg/day
106 27.2* NR 1.9 1.9 1.0 0
Rosuvastatin 20 mg/day 107 NR NR 1.9 0 0 0
FA 135 mg/day +
rosuvastatin 20 mg/day
110 NR NR 2.7 0.9 0 0
FA and rosuvastatin versus
simvastatin alone [28]
474 15.0 4.2 NR 0.7/0.2 (ALT/AST) 0.4 0
Simvastatin 40 mg/day 119 16.8 5.9 NR 0/0 0 0
FA 135 mg/day +
rosuvastatin 5 mg/day
118 13.6 5.1 NR 0/0 0 0
FA 135 mg/day +
rosuvastatin 10 mg/day
119 14.3 2.5 NR 0.8/0 0 0
FA 135 mg/day +
rosuvastatin 20 mg/day
118 15.3 3.4 NR 1.7/0.9 1.7 0
aALT or AST >3× ULN
bCreatine kinase >5× ULN
* Significant difference compared to the low-dose statin monotherapy (p<0.05)
AE, adverse event; FA, fenofibric acid; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FA, fenofibric acid; ULN, upper limit of
normal; NR, not reported
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[65–77]. Fibrates, alone or combined with other drugs, have
been demonstrated to reduce plasma levels of the small
dense LDL particles and to induce a LDL phenotype mod-
ification [1, 3, 78–83]. Furthermore, evidence exists that
fibrates improve inflammation-related parameters [10,
83–86]. There is also evidence that fibrates can alter HDL
particle distribution, which may play a role in the residual
CVD risk [87, 88].
The fibrate-statin combination may substantially reduce
the residual CVD risk in certain populations. For example,
the Action to Control Cardiovascular Risk in Diabetes (AC-
CORD) Lipid study included 5,518 patients with T2DM
treated with open-label simvastatin, who were randomised
to receive either masked fenofibrate or placebo for 4.7 years
[89]. The annualrateofthe primary outcome (firstoccurrence
of nonfatal myocardial infarction, nonfatal stroke, or death
from CVD causes) was 2.2 % in the fenofibrate group and
2.4 % in the placebo group [hazard ratio in the fenofibrate
group, 0.92; 95 % confidence interval (CI), 0.79–1.08; p0
0.32)]. The annual death rate was 1.5 % in the fenofibrate
group and 1.6 % in the placebo group (hazard ratio, 0.91;
95 % CI, 0.75–1.10; p00.33) [89]. However, in a pre-
specified analysis, a benefit regarding the primary outcome
rate (first occurrence of nonfatal myocardial infarction, non-
fatal stroke, or death from CVD causes) for patients with both
a high baseline TG level (≥204 mg/dl) and a low HDL-C
baseline level (≤34 mg/dl) was recognized for those on the
simvastatin + fenofibrate combination [89]. In fact, this ben-
efit was seen with no evidence of increased adverse events. In
the ACCORD Lipid study, elevations of CK ≥10 times the
upper limit of the normal range were similar in the fenofibrate
group (0.4 %) and in the placebo group (0.3 %, p00.83) and
the same rate of any myopathy/myositis/rhabdomyolysis was
reported in the 2 treatment groups (0.1 %) [89].
The evidence derived from randomized trials favors the use
of FA combined with a low- or moderate-dose statin for the
reduction of the residual CVD risk. This combination improves
all primary lipid variables. For example, the percentage of
patients simultaneously achieving LDL-C <100 mg/dl, non-
HDL-C <130 mg/dl, apoB <90 mg/dl, HDL-C >40 mg/dl
(men) or >50 mg/dl (women), and TG <150 mg/dl was ≥5-fold
higher with the combination of FA + low-dose statin compared
with low-dose statin monotherapy, and approximately 7-fold
higher with the combination of FA + moderate-dose statin
compared with moderate-dose statin monotherapy (p<0.001
for both) [27]. FA added to statin therapy has also repeatedly
been shown to reduce hsCRP levels. This may be of clinical
relevance since the reduction of hsCRP levels with rosuvastatin
has been associated with CVD event decrease [90]. However, it
should be mentioned that there is no clinical outcomes data to
show thattreatingthenon-LDL-CvariableswithFAwillreduce
major CVD endpoints.
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